
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Null Results in Brief |
Departments of 1 Epidemiology, 2 Head and Neck Surgery, 3 Pathology, and 4 Thoracic and Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints:Qingyi Wei, Department of Epidemiology, Unit 189, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3020; Fax: 713-563-0999. E-mail: qwei{at}mdanderson.org
| Introduction |
|---|
|
|
|---|
G at bp 1245 (C1245G) in the 1
-specific exon 7 that causes an amino acid substitution from serine to cysteine in codon 326 (Ser326Cys), potentially resulting in functional alteration (6). Several association studies of this hOGG1 C1245G polymorphism and cancer risk have generated contradicting results (3). Two recent larger breast cancer case-control studies yielded negative results (7, 8), but one recent study on SCCHN was positive (9). To further verify the possible role of the hOGG1 C1245G polymorphism in the etiology of SCCHN, we investigated the association between this polymorphism and the risk of SCCHN in a large hospital-based case-control study of 706 patients with SCCHN and 1,196 cancer-free control subjects. | Materials and Methods |
|---|
|
|
|---|
2 = 3.863; P = 0.145). Therefore, these controls were combined in the final analysis to increase the study power. These control subjects were frequency matched to the case subjects on age (±5 years), sex, and smoking status (never, ever, and current). Informed consent was obtained, and all subjects agreed to donate 30 mL of blood for biomarker testing and complete a detailed questionnaire eliciting their demographic, exposure to tobacco smoke and alcohol, and family history information. The study was approved by both our institutional review board and the Kelsey Seybold Foundation review board.
Genotyping
We used the published primer sequences and PCR-RFLP method (11) to amplify a 200-bp fragment of genomic DNA. The restriction enzyme Fnu4HI (New England Biolabs, Inc., Beverly, Massachusetts) was used to type the hOGG1 C1245G polymorphism. The variant allele was cut by the enzyme into two 100-bp fragments. The fragments were separated on a 3% agarose gel (Fig. 1). More than 10% of the samples were randomly selected for repeat assays, and the results were 100% concordant.
|
| Results |
|---|
|
|
|---|
|
Statistical Power
We had 80% power (two-sided test,
= 0.05) to detect an OR of 1.66 for GG homozygotes (5.8% in the controls), if this variant genotype is a risk genotype, compared with the CC+CG genotype. For both variant genotypes (CG + GG; 38.2% in the controls), the detectable OR was 1.31 compared with the CC genotype. Thus, our study had sufficient power to detect the ORs reported by Elahi et al. (9); i.e., OR 4.1, 95% CI 1.313.0 for GG homozygotes and OR 1.6, 95% CI 1.042.6 for variant genotypes (CG + GG).
| Discussion |
|---|
|
|
|---|
One reason for discrepant results in case-control studies is that the selection of the controls may be biased in terms of biomarkers of interest. The frequencies of the hOGG1 variant GG homozygous genotype (5.8%) and the G allele (0.220) in our study are consistent with those of 434 female white control subjects (4.6% and 0.241, respectively) in a recent Danish population-based nested breast cancer case-control study (7) but are higher than those of 338 white control subjects (1.8% and 0.130, respectively) in an earlier positive U.S. hospital-based orolaryngeal cancer case-control study (9). It is interesting that our cases and the cases of these two studies exhibited similar frequencies of GG homozygous genotype (5.5%, 5.2%, and 5.4%, respectively) and the G allele (0.211, 0.224, and 0.220). Other published case-control studies had much smaller numbers (<300 for each ethnic group) of controls with the frequency of the GG homozygous genotype ranging from
2% to 9% for white and between 13% and 24% for Asians (3, 12). The reported lowest GG homozygous genotype in control subjects was 1.8% in white (9) and the reported highest was 24.2% in Chinese (12).
Early association studies of Japanese populations suggested a possible role of the common variant of hOGG1 1245G in susceptibility to lung cancer, but the results of the most recent Japanese study of lung adenocarcinoma, the most plausible oxidative damage-induced cell type, did not support such an association (13). In the only published U.S. case-control study of 169 white patients with orolaryngeal cancer and 338 control subjects, Elahi et al. (9) found a significant association between the hOGG1 1245CG or 1245GG variant genotype and risk of orolaryngeal cancer, particularly in smokers and alcohol drinkers. Nevertheless, the positive finding of that study is weakened by the small sample size and the fact that the frequencies of variant alleles and genotypes were the lowest in the controls of that study among published studies and our study.
In conclusion, we did not find evidence to support an association between hOGG1 C1245G polymorphism and SCCHN risk in our study population. The limitation of our study is the hospital-based study design, and we cannot rule out the possibility of selection bias of subjects. Given that many genes are involved in the repair of oxidative damage (3), the role of oxidative damage and repair in SCCHN may be more efficiently investigated by using a phenotypic assay (14) and performing genotype and phenotype correlation analysis and by comprehensive study of the entire repair pathway (15).
| Acknowledgments |
|---|
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 12/ 1/03; accepted 2/ 2/04.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Hall, M. Hashibe, P. Boffetta, V. Gaborieau, N. Moullan, A. Chabrier, D. Zaridze, O. Shangina, N. Szeszenia-Dabrowska, D. Mates, et al. The association of sequence variants in DNA repair and cell cycle genes with cancers of the upper aerodigestive tract Carcinogenesis, March 1, 2007; 28(3): 665 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Paz-Elizur, R. Ben-Yosef, D. Elinger, A. Vexler, M. Krupsky, A. Berrebi, A. Shani, E. Schechtman, L. Freedman, and Z. Livneh Reduced Repair of the Oxidative 8-Oxoguanine DNA Damage and Risk of Head and Neck Cancer Cancer Res., December 15, 2006; 66(24): 11683 - 11689. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Hung, J. Hall, P. Brennan, and P. Boffetta Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review Am. J. Epidemiol., November 15, 2005; 162(10): 925 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, Q. Shi, Z. Liu, E. M. Sturgis, M. R. Spitz, and Q. Wei Polymorphisms of Methionine Synthase and Methionine Synthase Reductase and Risk of Squamous Cell Carcinoma of the Head and Neck: a Case-Control Analysis Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1188 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, Q. Shi, E. M. Sturgis, M. R. Spitz, W. K. Hong, and Q. Wei Thymidylate Synthase 5'- and 3'-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., December 1, 2004; 10(23): 7903 - 7910. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |